Cyclophosphamide, doxorubicin, and cisplatin in the treatment of advanced non-small cell lung cancer

Fifty-four patients with non-small cell lung cancer were treated with a combination of cyclophosphamide, doxorubicin, and cisplatin (CAP). A 35% response rate was seen, with a median survival of 380 days for the responders, compared to median survival times of 150 days for the nonresponders and 229...

Full description

Saved in:
Bibliographic Details
Published inCancer treatment reports Vol. 65; no. 11-12; p. 941
Main Authors Knost, J A, Greco, F A, Hande, K R, Richardson, R L, Fer, M F, Oldham, R K
Format Journal Article
LanguageEnglish
Published United States 01.11.1981
Subjects
Aged
Anorexia - chemically induced
Cisplatin - administration & dosage
Clinical Trials as Topic
Cyclophosphamide - administration & dosage
Doxorubicin - administration & dosage
Drug Synergism
Drug Therapy, Combination
Female
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Male
Middle Aged
Vomiting - chemically induced
Online AccessGet more information

Cover

More Information
Summary:Fifty-four patients with non-small cell lung cancer were treated with a combination of cyclophosphamide, doxorubicin, and cisplatin (CAP). A 35% response rate was seen, with a median survival of 380 days for the responders, compared to median survival times of 150 days for the nonresponders and 229 days for the group. Twenty-four percent of these patients had received prior treatment. All of the nonresponding patients had died by 438 days, whereas eight of 19 responders lived greater than 425 days. The survival curve the nonresponders was similar to that for a historical control group not given chemotherapy. These data indicate that this drug regimen has some efficacy in the treatment of non-small cell lung cancer.
ISSN:0361-5960